Kos joins Sutter Hill Ventures and other leading investors in backing Fathom Therapeutics's pioneering physics- and AI-powered drug discovery platform

Kos 与 Sutter Hill Ventures 及其他领先投资者共同支持 Fathom Therapeutics 开创性的基于物理和人工智能的药物发现平台

NEW YORK and ATHENS, Greece

纽约和希腊雅典

,

，

Nov. 6, 2026

2026年11月6日

/PRNewswire/ -- Kos Biotechnology Partners ('Kos'), a global life sciences investment firm bridging the U.S. and European biopharma ecosystems, today announced its investment in Fathom Therapeutics, a leading drug design company pioneering the application of quantum chemistry, physics-based molecular simulations, and artificial intelligence to discover and develop next-generation small molecule medicines..

/美通社/ -- 全球生命科学投资公司Kos Biotechnology Partners（简称“Kos”）致力于连接美国与欧洲生物医药生态系统，今日宣布投资Fathom Therapeutics。Fathom Therapeutics是一家领先的药物设计公司，率先将量子化学、基于物理的分子模拟以及人工智能应用于下一代小分子药物的发现与开发。

The investment was made through Kos BioVentures, the firm's inaugural life sciences fund, as part of Fathom Therapeutics's Series A financing. Sutter Hill Ventures led the oversubscribed $55 million financing, along with other leading investors.

该投资通过该公司的首只生命科学基金 Kos BioVentures 进行，作为 Fathom Therapeutics A 轮融资的一部分。Sutter Hill Ventures 与其他领先投资者共同领投了这轮超额认购的 5,500 万美元融资。

Fathom Therapeutics was founded by a team of world-renowned computational scientists, led by Chief Executive Officer Dr. Huafeng Xu, a pioneer in the field of computational drug design. The company is developing a new paradigm for drug discovery through its proprietary Microcosmos platform, which combines advanced physics-based simulations and AI to predict how proteins move and interact with drug molecules at atomic resolution..

Fathom Therapeutics 由一支世界知名的计算科学家团队创立，由首席执行官徐华峰博士领导，他是计算药物设计领域的先驱。该公司正在通过其专有的 Microcosmos 平台开发一种新的药物发现范式，该平台结合先进的基于物理的模拟和人工智能技术，以原子分辨率预测蛋白质的运动及其与药物分子的相互作用。

'

'

Fathom Therapeutics possesses industry-leading expertise in two of the most crucial areas in next-generation drug discovery: quantum chemistry and artificial intelligence

Fathom Therapeutics 在下一代药物发现的两个最关键领域——量子化学和人工智能——拥有行业领先的专业知识。

,' said Dr. Simos Simeonidis, Co-Founder and Managing Partner of Kos Biotechnology Partners. 'The ability to model molecular interactions with unprecedented speed and precision has the potential to fundamentally change how we discover medicines, particularly against biological targets that have historically been considered undruggable.

Kos Biotechnology Partners 联合创始人兼管理合伙人 Simos Simeonidis 博士表示：“以前所未有的速度和精度模拟分子相互作用的能力，有望从根本上改变我们发现药物的方式，尤其是针对那些历来被认为难以成药的生物靶点。”

We are very excited to invest in Huafeng and his truly exceptional team, alongside a distinguished group of investors, to help advance this groundbreaking technology and translate its potential into meaningful therapeutic breakthroughs for patients.'.

我们非常兴奋能与一群杰出的投资者一道，投资华丰及其真正卓越的团队，共同推动这项突破性技术的发展，并将其潜力转化为为患者带来实质性治疗意义的突破。

'

'

We welcome Simos, Alex and the deeply experienced Kos team to our syndicate of investors, and we are looking forward to working with them as we push forward with our mission to develop innovative therapeutics

我们欢迎西蒙诺斯、亚历克斯以及经验深厚的Kos团队加入我们的投资者联盟，并期待在我们推进开发创新疗法的使命过程中与他们携手合作。

,' said Dr. Huafeng Xu, co-founder and Chief Executive Officer of Fathom Therapeutics.

Fathom Therapeutics 联合创始人兼首席执行官徐华峰博士表示。

'

'

The next generation of biopharmaceutical innovation will increasingly emerge from the intersection of computational science, AI, and experimental biology

下一代生物制药创新将越来越多地涌现于计算科学、人工智能与实验生物学的交叉领域。

,' said Alex Tzoukas, Co-Founder and Managing Partner of Kos Biotechnology Partners. 'Fathom Therapeutics has assembled a world-class team with deep expertise in molecular simulation and drug discovery, supported by a platform that has already demonstrated compelling early results. Our investment reflects Kos's conviction that differentiated technologies that improve drug discovery productivity and address previously inaccessible targets can create significant value for patients and investors alike.

Kos Biotechnology Partners 联合创始人兼管理合伙人 Alex Tzoukas 表示：“Fathom Therapeutics 组建了一支在分子模拟和药物发现领域拥有深厚专业知识的世界级团队，并由一个已展现出令人瞩目的早期成果的平台提供支持。我们的投资体现了 Kos 的信念：那些能够提高药物发现生产力并攻克以往难以触及的靶点的差异化技术，可以为患者和投资者创造巨大价值。”

We look forward to supporting Fathom Therapeutics as it scales its platform, advances its internal pipeline, and expands its strategic partnerships.'.

我们期待支持 Fathom Therapeutics 扩大其平台规模、推进内部研发管线并拓展战略合作伙伴关系。

In addition to Huafeng Xu, PhD, Fathom Therapeutics was co-founded by Yujie Wu, PhD, Chief Technology Officer, and Jesús Izaguirre, PhD, Chief Computational Scientist. The team's pioneering work spans molecular simulation, computational chemistry, and drug discovery, and includes the scientists behind the Anton supercomputer and widely adopted computational methods for predicting protein-drug interactions.

除徐华峰博士外，Fathom Therapeutics 还由首席技术官吴玉杰博士和首席计算科学家 Jesús Izaguirre 博士联合创立。该团队的开创性工作涵盖分子模拟、计算化学和药物发现领域，其中包括 Anton 超级计算机背后的科学家，以及广泛用于预测蛋白质-药物相互作用的计算方法。

The broader leadership team brings significant drug development experience..

更广泛的管理团队拥有丰富的药物开发经验。

The investment further strengthens Kos's portfolio of innovative life sciences companies and reinforces its strategy of supporting breakthrough therapeutic technologies, differentiated drug discovery platforms, and globally competitive biopharmaceutical businesses.

此次投资进一步丰富了 Kos 在创新型生命科学公司领域的投资组合，并强化了其支持突破性治疗技术、差异化药物发现平台以及具有全球竞争力的生物医药企业的战略。

About Kos Biotechnology Partners

关于 Kos 生物技术合作伙伴

Kos Biotechnology Partners is a global life sciences investment firm based in New York and Athens, Greece. Founded by Dr. Simos Simeonidis and Alex Tzoukas, Kos manages $125 million in assets and invests across all stages of development in therapeutic breakthroughs, biodefense, and tech-enabled pharma services.

Kos Biotechnology Partners 是一家全球生命科学投资公司，总部位于纽约和希腊雅典。由 Simos Simeonidis 博士和 Alex Tzoukas 创立，Kos 管理着 1.25 亿美元的资产，投资于治疗突破、生物防御以及技术赋能的制药服务的所有发展阶段。

For more information, visit kosbp.com..

更多信息，请访问 kosbp.com。

Media Contact

媒体联系人

Kos Biotechnology Partners

Kos 生物技术合作伙伴

info@kosbp.com

info@kosbp.com

SOURCE Kos Biotechnology Partners

来源：Kos 生物技术合作伙伴